Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ash-hematology.bsky.social
December 4, 2024 at 5:35 PM
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from #ASH24. 🧵 #ASHEducation #ASHKudos cc @ash-hematology.bsky.social
Get excited for this year's #MajorPROsASH! I'm currently reviewing >300 patient-reported outcomes (PRO) abstracts from #ASH24 to curate next week's list of the top 20 best
@ash-hematology.bsky.social quality of life abstracts. Stay tuned!
@ash-hematology.bsky.social quality of life abstracts. Stay tuned!
November 26, 2024 at 9:13 PM
Get excited for this year's #MajorPROsASH! I'm currently reviewing >300 patient-reported outcomes (PRO) abstracts from #ASH24 to curate next week's list of the top 20 best
@ash-hematology.bsky.social quality of life abstracts. Stay tuned!
@ash-hematology.bsky.social quality of life abstracts. Stay tuned!
Poster #ASH24: 50% of pts with NHL have financial toxicity! In MV model, FT strongly associated with younger age at diagnosis, income, employment and getting systemic chemo. #lymsm #MajorPROsASH
December 9, 2024 at 6:12 PM
Poster #ASH24: 50% of pts with NHL have financial toxicity! In MV model, FT strongly associated with younger age at diagnosis, income, employment and getting systemic chemo. #lymsm #MajorPROsASH
Sneak peek of my mentee Dr. Pizzuti's heatmap PRO analysis PROs from our BISON-PRO Quality of Life Study (http://bison-pro.org). His abstract is at tonight's #ASH24 poster session; big congrats on his ASH Achievement Award! #MajorPROsASH cc @cuhematology.bsky.social @vpizzuti.bsky.social
December 9, 2024 at 8:17 PM
Sneak peek of my mentee Dr. Pizzuti's heatmap PRO analysis PROs from our BISON-PRO Quality of Life Study (http://bison-pro.org). His abstract is at tonight's #ASH24 poster session; big congrats on his ASH Achievement Award! #MajorPROsASH cc @cuhematology.bsky.social @vpizzuti.bsky.social
Poster #ASH24: better improvements in pain & fatigue at D+90 post #mmsm CAR in underrepresented minorities. However, also notice 29% of minorities with worsening fatigue; subgroup analysis to better understand predictors of better vs worse fatigue. #MajorPROsASH
December 10, 2024 at 7:50 PM
Poster #ASH24: better improvements in pain & fatigue at D+90 post #mmsm CAR in underrepresented minorities. However, also notice 29% of minorities with worsening fatigue; subgroup analysis to better understand predictors of better vs worse fatigue. #MajorPROsASH
Honorable mention #MajorPROsASH: real-world PROs w/ 1L dara
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
December 9, 2024 at 10:59 PM
Honorable mention #MajorPROsASH: real-world PROs w/ 1L dara
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
November 25, 2025 at 8:49 PM
Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
Poster #ASH24: less deterioration of phys fx in glofi arm, also less pain (including sustained improvement in pain) & lymphoma-related symptoms in glofi arm. #MajorPROsASH #lymsm
December 9, 2024 at 11:15 PM
Poster #ASH24: less deterioration of phys fx in glofi arm, also less pain (including sustained improvement in pain) & lymphoma-related symptoms in glofi arm. #MajorPROsASH #lymsm
From #ASH24 oral: CTCL global QOL scores & pruritis improve in both responders & non-responders (non-responders just have a delayed improvement). No pts with Sezary had severe CTCL symptoms by week 81! PRO benefit in both SS & MF. #lymsm #MajorPROsASH
December 8, 2024 at 6:28 PM
From #ASH24 oral: CTCL global QOL scores & pruritis improve in both responders & non-responders (non-responders just have a delayed improvement). No pts with Sezary had severe CTCL symptoms by week 81! PRO benefit in both SS & MF. #lymsm #MajorPROsASH
Honorable mention #MajorPROsASH: PROs pts with bleeding d/o of unknown cause (BDUC)
- 97 pts completed RAND-36
- significantly worse phys health, energy, social fxn & pain in BDUC vs general population
Important findings in wholly understudied pt population. #ASH24 #hemetwitter
- 97 pts completed RAND-36
- significantly worse phys health, energy, social fxn & pain in BDUC vs general population
Important findings in wholly understudied pt population. #ASH24 #hemetwitter
December 7, 2024 at 7:42 PM
Honorable mention #MajorPROsASH: PROs pts with bleeding d/o of unknown cause (BDUC)
- 97 pts completed RAND-36
- significantly worse phys health, energy, social fxn & pain in BDUC vs general population
Important findings in wholly understudied pt population. #ASH24 #hemetwitter
- 97 pts completed RAND-36
- significantly worse phys health, energy, social fxn & pain in BDUC vs general population
Important findings in wholly understudied pt population. #ASH24 #hemetwitter
#ASH24 oral: significant & sustained improvements in pain w/ exercise interventions. Fatigue improved but then significantly worsened after intervention. Further studies needed on promoting sustained exercise & fatigue improvements in #mmsm. #MajorPROsASH
December 9, 2024 at 3:04 AM
#ASH24 oral: significant & sustained improvements in pain w/ exercise interventions. Fatigue improved but then significantly worsened after intervention. Further studies needed on promoting sustained exercise & fatigue improvements in #mmsm. #MajorPROsASH
Masterful #ASH24 oral on PROs in HOVON141 (#ASHKudos to @ASH_hematology for including PROs in primary trial sessions!) 🧵
- 224 pts, 83% PRO completion 2 yrs, down to 52% at 3 yrs
- improvement in global QOL above MID which is sustained (only 15% had worsening)
1/ #MajorPROsASH
- 224 pts, 83% PRO completion 2 yrs, down to 52% at 3 yrs
- improvement in global QOL above MID which is sustained (only 15% had worsening)
1/ #MajorPROsASH
December 10, 2024 at 5:51 PM
Masterful #ASH24 oral on PROs in HOVON141 (#ASHKudos to @ASH_hematology for including PROs in primary trial sessions!) 🧵
- 224 pts, 83% PRO completion 2 yrs, down to 52% at 3 yrs
- improvement in global QOL above MID which is sustained (only 15% had worsening)
1/ #MajorPROsASH
- 224 pts, 83% PRO completion 2 yrs, down to 52% at 3 yrs
- improvement in global QOL above MID which is sustained (only 15% had worsening)
1/ #MajorPROsASH
Happy #ASH24 week! Today, I'll be tweeting my top 20 patient-reported outcomes (PROs) abstracts on #MajorPROsASH. Follow the hashtag for the most interesting and provocative quality of life studies from the ASH annual meeting. cc @ash-hematology.bsky.social
December 3, 2024 at 1:03 PM
Happy #ASH24 week! Today, I'll be tweeting my top 20 patient-reported outcomes (PROs) abstracts on #MajorPROsASH. Follow the hashtag for the most interesting and provocative quality of life studies from the ASH annual meeting. cc @ash-hematology.bsky.social
Poster #ASH24: visualization of increase in CIPN by EOT followed by resolution in long-term follow-up. CIPN worse in hands/fingers as compared to toes. #lymsm #MajorPROsASH
December 7, 2024 at 8:25 PM
Poster #ASH24: visualization of increase in CIPN by EOT followed by resolution in long-term follow-up. CIPN worse in hands/fingers as compared to toes. #lymsm #MajorPROsASH
Honorable mention #MajorPROsASH: splenic RT before allo MF @michaelsbinkley
- 10 pts, symptomatic splenomegaly➡️MPN-SAF TSS PRO
- D+90 post allo: sx splenomegaly better by 20 pts (MID is ~1.5-2 points)
Phenomenal example of PRO integration into early-phase trials. #ASH24 #mpnsm
- 10 pts, symptomatic splenomegaly➡️MPN-SAF TSS PRO
- D+90 post allo: sx splenomegaly better by 20 pts (MID is ~1.5-2 points)
Phenomenal example of PRO integration into early-phase trials. #ASH24 #mpnsm
December 8, 2024 at 5:33 PM
Honorable mention #MajorPROsASH: splenic RT before allo MF @michaelsbinkley
- 10 pts, symptomatic splenomegaly➡️MPN-SAF TSS PRO
- D+90 post allo: sx splenomegaly better by 20 pts (MID is ~1.5-2 points)
Phenomenal example of PRO integration into early-phase trials. #ASH24 #mpnsm
- 10 pts, symptomatic splenomegaly➡️MPN-SAF TSS PRO
- D+90 post allo: sx splenomegaly better by 20 pts (MID is ~1.5-2 points)
Phenomenal example of PRO integration into early-phase trials. #ASH24 #mpnsm
19 – #MajorPROsASH – 2749 Rangel
Sexual health & QoL in #leusm survivors: Significantly worse sexual function, pain/discomfort, & communication w/ partners vs matched healthy controls, despite similar self-esteem. Major unmet survivorship domain & need for multiD approach. #ASH25 @ash.hematology.org
Sexual health & QoL in #leusm survivors: Significantly worse sexual function, pain/discomfort, & communication w/ partners vs matched healthy controls, despite similar self-esteem. Major unmet survivorship domain & need for multiD approach. #ASH25 @ash.hematology.org
December 1, 2025 at 5:20 PM
19 – #MajorPROsASH – 2749 Rangel
Sexual health & QoL in #leusm survivors: Significantly worse sexual function, pain/discomfort, & communication w/ partners vs matched healthy controls, despite similar self-esteem. Major unmet survivorship domain & need for multiD approach. #ASH25 @ash.hematology.org
Sexual health & QoL in #leusm survivors: Significantly worse sexual function, pain/discomfort, & communication w/ partners vs matched healthy controls, despite similar self-esteem. Major unmet survivorship domain & need for multiD approach. #ASH25 @ash.hematology.org
14 – #MajorPROsASH – 4278 Guilcher
Children & AYA pts w/ #sicklecell disease receiving alloSCT: substantial QoL improvements and low decisional regret up to 3 yrs after allo. Study supports shared decision-making in #SCD that includes long-term⬆️QoL outcomes. #bmtsm #ASH25 @ash.hematology.org
Children & AYA pts w/ #sicklecell disease receiving alloSCT: substantial QoL improvements and low decisional regret up to 3 yrs after allo. Study supports shared decision-making in #SCD that includes long-term⬆️QoL outcomes. #bmtsm #ASH25 @ash.hematology.org
December 2, 2025 at 6:28 PM
14 – #MajorPROsASH – 4278 Guilcher
Children & AYA pts w/ #sicklecell disease receiving alloSCT: substantial QoL improvements and low decisional regret up to 3 yrs after allo. Study supports shared decision-making in #SCD that includes long-term⬆️QoL outcomes. #bmtsm #ASH25 @ash.hematology.org
Children & AYA pts w/ #sicklecell disease receiving alloSCT: substantial QoL improvements and low decisional regret up to 3 yrs after allo. Study supports shared decision-making in #SCD that includes long-term⬆️QoL outcomes. #bmtsm #ASH25 @ash.hematology.org
We often hear complaints from pharma and/or cooperative groups that PROs are too burdensome; look at these objective data saying otherwise!
Congratulations to @GitaThanaMD @BiostatGirl et al. on this trial.
2/2 #MajorPROsASH #ASH24 #lymsm
Congratulations to @GitaThanaMD @BiostatGirl et al. on this trial.
2/2 #MajorPROsASH #ASH24 #lymsm
December 8, 2024 at 12:43 AM
We often hear complaints from pharma and/or cooperative groups that PROs are too burdensome; look at these objective data saying otherwise!
Congratulations to @GitaThanaMD @BiostatGirl et al. on this trial.
2/2 #MajorPROsASH #ASH24 #lymsm
Congratulations to @GitaThanaMD @BiostatGirl et al. on this trial.
2/2 #MajorPROsASH #ASH24 #lymsm
17 – #MajorPROsASH – 2117 Schwaner
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
December 1, 2025 at 7:09 PM
17 – #MajorPROsASH – 2117 Schwaner
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
Poster #ASH24: fascinating to see that GIV cohort had much worse longitudinal QOL, functioning & symptom burden over time as compared to GV/RV (also worse diarrhea). Great demonstration of how PROs can complement efficacy outcomes! No need for GIV. #lymsm #MajorPROsASH
December 8, 2024 at 9:12 PM
Poster #ASH24: fascinating to see that GIV cohort had much worse longitudinal QOL, functioning & symptom burden over time as compared to GV/RV (also worse diarrhea). Great demonstration of how PROs can complement efficacy outcomes! No need for GIV. #lymsm #MajorPROsASH
Honorable mention #MajorPROsASH: PROs MGUS & SMM #ASH24
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
December 7, 2024 at 9:32 PM
Honorable mention #MajorPROsASH: PROs MGUS & SMM #ASH24
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
7. #MajorPROsASH: PROs 3 exercise interventions #mmsm @JanineMJoseph
- 76 pts, mean age 63
- fatigue improved after 6 mo w/ resistance training, but benefits lost after training
- pain improvements not lost after supervised in-person
Sustained exercise supervision needed. #ASH24.
- 76 pts, mean age 63
- fatigue improved after 6 mo w/ resistance training, but benefits lost after training
- pain improvements not lost after supervised in-person
Sustained exercise supervision needed. #ASH24.
December 3, 2024 at 5:04 PM
7. #MajorPROsASH: PROs 3 exercise interventions #mmsm @JanineMJoseph
- 76 pts, mean age 63
- fatigue improved after 6 mo w/ resistance training, but benefits lost after training
- pain improvements not lost after supervised in-person
Sustained exercise supervision needed. #ASH24.
- 76 pts, mean age 63
- fatigue improved after 6 mo w/ resistance training, but benefits lost after training
- pain improvements not lost after supervised in-person
Sustained exercise supervision needed. #ASH24.
Poster #ASH24: figures speak for themselves!
- improvement in sx burden & impact of sx w/ cilta-cel
- more pts with meaningful improvement in sx w/ cilta-cel
- much better global QOL & phys/emotional/role/social fxn w/ cilta-cel
Comprehensive #mmsm PROs! #MajorPROsASH
- improvement in sx burden & impact of sx w/ cilta-cel
- more pts with meaningful improvement in sx w/ cilta-cel
- much better global QOL & phys/emotional/role/social fxn w/ cilta-cel
Comprehensive #mmsm PROs! #MajorPROsASH
December 7, 2024 at 8:42 PM
Poster #ASH24: figures speak for themselves!
- improvement in sx burden & impact of sx w/ cilta-cel
- more pts with meaningful improvement in sx w/ cilta-cel
- much better global QOL & phys/emotional/role/social fxn w/ cilta-cel
Comprehensive #mmsm PROs! #MajorPROsASH
- improvement in sx burden & impact of sx w/ cilta-cel
- more pts with meaningful improvement in sx w/ cilta-cel
- much better global QOL & phys/emotional/role/social fxn w/ cilta-cel
Comprehensive #mmsm PROs! #MajorPROsASH
Honorable mention #MajorPROsASH: PROs in phase I trials
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
December 9, 2024 at 10:44 PM
Honorable mention #MajorPROsASH: PROs in phase I trials
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Phenomenal effort by @EthanBasch1 & @BiostatGirl on how PRO-CTCAE & CTCAE can aid in dose finding and provide a comprehensive picture of safety & tolerability. No excuse not to include PRO-CTCAE in early-phase trials. #ASH24
Honorable mention #MajorPROsASH: PROs in AYAs receiving blina
- sig improvements in FACT-LEU TOI & emotional wellbeing by end of consolidation
- however, significantly worse social wellbeing by tx completion
Need to better support AYA pts who are pump-dependent for 28 days. #leusm #ASH24
- sig improvements in FACT-LEU TOI & emotional wellbeing by end of consolidation
- however, significantly worse social wellbeing by tx completion
Need to better support AYA pts who are pump-dependent for 28 days. #leusm #ASH24
December 7, 2024 at 7:52 PM
Honorable mention #MajorPROsASH: PROs in AYAs receiving blina
- sig improvements in FACT-LEU TOI & emotional wellbeing by end of consolidation
- however, significantly worse social wellbeing by tx completion
Need to better support AYA pts who are pump-dependent for 28 days. #leusm #ASH24
- sig improvements in FACT-LEU TOI & emotional wellbeing by end of consolidation
- however, significantly worse social wellbeing by tx completion
Need to better support AYA pts who are pump-dependent for 28 days. #leusm #ASH24